Celgene Reports Update on its Collaboration with Jounce Therapeutics

Shots:

• Jounce to receive $50M up front, $180M as development & regulatory milestones, $300M as commercial milestones, royalties on global sales and will retain WW rights to its pipeline including vopratelimab, JTX-4014 and all discovery programs
• Celgene to get WW rights to develop & commercialize Jounce’s JTX-8064, an anti-leukocyte immunoglobulin like receptor B2 (LILRB2) Ab, focuses on tumor-associated macrophages. Additionally, Celgene signed a mutual agreement with Jounce to terminate its 2016 deal which focuses on the development of immuno-oncology therapies
• Jounce’s vopratelimab is a mAb JTX-4014 targeting ICOS, a protein present on the surface of T-cells found in solid tumors, assessed in ICONIC P-I/II study. JTX-4014 is an IgG4 mAb designed to block binding to PD-L1 and PD-L2 being evaluated in P-I study

Click here to­ read full press release/ article | Ref: GlobeNewsWire | Image: The Street